Global Liquid Biopsy Market Forecast Reveals a 15.2% CAGR Growth Through 2035 Amid Rising Demand for Non Invasive Cancer Diagnostics – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Liquid Biopsy Market 2018-2035: Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, End-users, Stage of Development, Type of Product, Type of Technique, Application Area and Key Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.

The global liquid biopsy market is projected to expand significantly, exhibiting a robust compounded annual growth rate (CAGR) of 15.2% through the year 2035. The report underlines key factors propelling market growth, including the increasing demand for early cancer detection and the surging inclination toward non invasive diagnostic methods.

As the world grapples with a mounting burden of cancer cases, medical communities worldwide are intensively exploring early detection techniques that could potentially improve treatment outcomes and patient survival rates. Liquid biopsy is hailed as a transformative approach in this research domain, especially for its targets in non invasive cancer diagnosis, patient monitoring, and precision medicine.

According to the analysis detailed in the research study, liquid biopsy, due to its minimally invasive nature and improved accuracy, is becoming an indispensable tool in oncology, responding to the critical need for early cancer detection strategies. The study provides an in-depth market distribution by application, target disease indication, type of circulating biomarker, type of sample, end-users, stage of development, type of technique, and geographical regions.

Furthermore, the research publication signals an era of collaboration and innovation within the liquid biopsy field, highlighted by increasing partnerships and funding initiatives, that are set to redefine the landscape of cancer diagnostics. These collaborations are not only accelerating the development of state-of-the-art liquid biopsy products but also fostering advancements in their commercialization.

Key Market Insights

• North America holds a significant share of the liquid biopsy market, with numerous companies actively investing in research and development. Asia-Pacific regions are identified as high growth areas, owing to recent advancements and adoptions of such tests. The European market is also a strong contributor to the liquid biopsy market space.
• An increase in regulatory approvals and reimbursement for liquid biopsy tests, such as the Guardant360 CDx, indicates a growing acceptance and reliance on these methods for cancer management.
• Stakeholders have established numerous strategic collaborations aimed at enhancing their diagnostics offerings, reflecting the sector’s dynamic nature and its emphasis on constant technological evolution.

The study unpacks the distribution of the current and forecasted liquid biopsy market opportunity across various applications, such as early cancer detection, patient monitoring, and therapy selection. The market analysis further delves into the roles of different market stakeholders and depicts a detailed competitive landscape, indicating that over 160 manufacturers are innovating in this space, with North America as the innovation hotspot.

The liquid biopsy market research offers invaluable insights for healthcare professionals, cancer researchers, diagnostic companies, and policymakers, providing them a detailed exploration of this groundbreaking technology. It serves as a crucial resource for understanding the pivotal role liquid biopsy plays today and its anticipated impact on the future of cancer diagnostics.

The emergence of liquid biopsy is a testament to the healthcare industry’s ongoing commitment to enhance the precision and patient-friendliness of cancer diagnostics, with this market study standing as an essential read for those committed to the advancement of cancer care.

Regional Analysis and Market Trends

Segment-wise, the report extensively covers the predominance of circulating tumor DNA among other types of circulating biomarkers, which is expected to dominate the market share. Moreover, highlighting the current state and regional analysis of the liquid biopsy market, the research emphasizes North America and Europe as traditional hubs, while underscoring the rapid rise of the Asia-Pacific region in the liquid biopsy domain.

The report provides a 360-degree view of influential market trends, including the increasing prevalence of cancer, regulatory support, technological advancements, and escalating global healthcare expenditures on cancer care, making the publication an indispensable resource for stakeholders looking to navigate the complexities of the liquid biopsy market.

Key Attributes:

Key Topics Covered:

• Non-Invasive Cancer Screening And Diagnosis
• Liquid Biopsy: Market Landscape
• Company Profiles
• Partnerships And Collaborations
• Funding And Investment Analysis
• Product Competitiveness Analysis
• Big Pharma Initiatives
• Key Acquisition Targets
• Other Non-Invasive Cancer Diagnostics
• Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges
• Global Liquid Biopsy Market
• Liquid Biopsy Market, By Application
• Liquid Biopsy Market, By Target Disease Indication
• Liquid Biopsy Market, By Type Of Circulating Biomarker
• Liquid Biopsy Market, By Type Of Sample
• Liquid Biopsy Market, By Type Of End-User
• Liquid Biopsy Market, By Key Geographical Regions

Companies Mentioned

• 4basebio
• 4D Lifetec
• 50K Ventures
• 8VC
• A&G Pharmaceutical
• Abbott
• AccessHope
• AccuraGen
• Ackermans & van Haaren
• Acobiom
• ACT Genomics
• Acuamark Diagnostics
• Agendia
• Agilent Technologies
• aiGENE
• Alligator Bioscience
• Ally Bridge Group
• Amadix
• Amgen
• Anchor Molecular
• ANGLE
• Annoroad Gene Technology
• Anthill Ventures
• Apostle
• Arboretum Ventures
• ARCH Venture Partners
• Archangel Investors
• ArcherDX
• ARNA Genomics
• Arquer Diagnostics
• Artiman Ventures
• ARUP Laboratories
• Arvinas
• Astellas Pharma
• AstraZeneca
• Asuragen
• Aurum Ventures
• AWSensors
• BeAble Capital
• BGI Genomics
• Bio-Rad
• BioCaptiva
• Biocartis
• Biocept
• BioChain
• Biodesix
• BioFluidica
• Biological Dynamics
• BlackRock
• Blue Pool Capital
• BNO BIO
• Boehringer Ingelheim
• Boulder Ventures
• BrightEdge
• Bristol Myers Squibb
• Broadway Angels
• BW Ventures
• C2i Genomics
• Canostix
• Caris Life Sciences
• Carrum Health
• CDBI Partners
• Celgene
• CellMax Life
• Cepheid
• CPH Capital
• CRF Investment
• Curta
• Cyclomics
• Decheng Capital
• Delee
• Denlux Capital
• DermTech
• Detong Capital
• Devyser
• DiaCarta
• DiaDx
• Diagnolita
• DSC Investment
• DT Capital
• Dxcover
• EarlyDx
• EDBI
• EDP Biotech
• Eisai
• Eli Lilly
• Elicio Therapeutics
• Enterix
• Epic Sciences
• Exact Sciences
• ExBiome
• Exosomics
• F-star
• Faro Capital
• Flatiron Health
• Fluxion Biosciences
• Forestone Capital
• Fortune Fountain Capital
• Fosun Pharmaceutical
• Freenome
• Fulgent Genetics
• Furong Investment
• GeneCast Biotechnology
• GENinCode
• Genomictree
• Genostics
• GILUPI
• Glycanostics
• GRAIL
• Guardant Health
• Gurnet Point Capital
• Hadean Ventures
• Hatteras Venture Partners
• HDFC
• HEDA Ventures
• Helio Genomics
• HighLight Capital
• Horizon
• Hummingbird Diagnostics
• Hyderabad Angels
• ICBC International
• Ikonisys
• Illumina
• Imperial Innovations
• Incyte
• Inivata
• Innovatus Capital Partners
• Inova Strategic Investments
• INOVIQ
• Inventures
• Invest4OncoDNA
• INVITEK Molecular
• IP Group
• iSelect Fund
• IVDiagnostics
• Janus Henderson Investors
• Jennison Associates
• Johnson & Johnson
• Junci Investment
• Junson Capital
• KEODES
• Kexin Capital
• Khosla Ventures
• Labcorp
• LeapFrog Investments
• Lexent Bio
• Lilly Asia Ventures
• Linden Capital Partners
• Longwood Fund
• Loyal Valley Capital
• LU Holding
• Lucence
• LungLife AI
• LYFE Capital
• MagBio Genomics
• McKesson Ventures
• MDxHealth
• MedGenome
• Merck
• MiCareo
• Micronoma
• Miltenyi Biotec
• Minomic
• miR Scientific
• Mirati Therapeutics
• MiRXES
• Mitsui
• Multimmune
• Mumbai Angels
• myNEO
• Myriad Genetics
• Nan Fung Group
• Nanostics
• NantHealth
• Natera
• Naveris
• NeoGeneStar
• Nonacus
• Northpond Ventures
• Novartis
• Novigenix
• Novo Holdings
• NRG Oncology
• nRichDX
• Nucleix
• NVIGEN
• Ochsner Health
• OCI Bio Investments
• Old College Capital
• Omnigen
• Oncimmune
• OncoDNA
• OrbiMed
• Pacific Edge
• Parampara Fund
• PBM Capital
• Perceptive Advisors
• PeriRx
• Personalis
• Pfizer
• Pillar Biosciences
• Positive Bioscience
• Predicine
• Premier
• Promega
• Prosperico Venture
• Provista Diagnostics
• Proxima Ventures
• Q2 Solutions
• QIAGEN
• Quest Diagnostics
• Qure
• R-Cubed Capital
• Rarecells
• Resolution Bioscience
• RGCC Group
• Rock Springs Capital
• Rongsheng Investment
• RT Ventures
• SAGA Diagnostics
• Saha Fund
• Sambrinvest
• Sands Capital
• Sangel Capital
• Sansure Biotec
• Saphetor
• Scottish Enterprise
• ScreenCell
• Sebela Pharmaceuticals
• SensID
• Sequoia Capital
• Servier
• SIMFO
• Singlera Genomics
• Sky Ventures
• Sofina
• Sofinim
• SoftBank Ventures
• Soleus Capital
• Sozo Ventures
• SPD Scientific
• StageZero Life Sciences
• StartX
• Sutter Hill Ventures
• Swelife
• SYMBIOSIS
• Takara Bio
• Tecan
• Tempus
• Tesis Biosciences
• Thermo Fisher Scientific
• Todos Medical
• Virtus Health
• VolitionRx
• Vortex Biosciences
• Windham Venture Partners
• Wisemont Capital
• WntResearch
• WRF Capital
• WS Investment
• X-ZELL
• XboXLab
• Yemaachi Biotech
• Yi Fang Group
• Zehou Capital
• ZERO Prostate Cancer
• Zinexts Life Science
• Zodius
• Zogen Genética Molecular

For more information about this report visit https://www.researchandmarkets.com/r/4y9w53

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900